Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing a favorable safety and efficacy profile with earlier and deeper responses in cohort 3 compared to cohorts 1 and 2 [1][2][3] Group 1: Clinical Trial Data - The Phase 1 trial included 48 patients, with 32 receiving soquelitinib and 12 receiving placebo, demonstrating significant responses in EASI 75 and IGA 0 or 1 endpoints [3][4] - The percent reduction in mean EASI scores at 28 days was 54.6% for cohorts 1 and 2 combined and 71.1% for cohort 3, compared to 30.6% and 42.1% for placebo, respectively [7][9] - All cohorts showed significant separation from placebo, with the combined soquelitinib treatment group being significantly superior at day 28 (p=0.03) [9][10] Group 2: Safety and Efficacy - Soquelitinib was well tolerated, with no dose-limiting toxicities and only one treatment-related adverse event reported [15] - Biomarker studies indicated reductions in inflammatory cytokines and an increase in T regulatory cells, supporting the drug's mechanism of action [16] Group 3: Future Directions - The trial protocol has been amended to include an additional 24 patients at the 200 mg twice per day dose for an extended treatment period of 8 weeks, aiming to evaluate stronger efficacy [2][18] - The company plans to initiate a Phase 2 trial before the end of the year based on the interim results [2][18] Group 4: Presentation and Communication - Data from the trial will be presented at the Society for Investigative Dermatology 2025 Annual Meeting, with details shared during the company's first quarter 2025 business update conference call [21][22]